GV
GV Management Company, LLC, formerly known as Google Ventures, serves as the venture capital arm of Alphabet Inc., established in 2009 and headquartered in Mountain View, California, with additional offices in Boston, New York, Cambridge, and London. The firm specializes in growth capital investments across various stages, including seed, early, mid, and late stages, focusing on sectors such as life sciences, healthcare, artificial intelligence, robotics, cyber security, and agriculture. GV has invested in over 300 companies, seeking to support startups that aim to innovate and transform industries. The firm typically invests up to $50 million, with smaller amounts allocated to early-stage ventures. GV provides its portfolio companies with exceptional support by connecting them with Google's resources and talent, leveraging a team of experts in engineering, design, science, and marketing to enhance their growth potential.
Strella Biotechnology, Inc. designs and manufactures sensors based device that maximizes the freshness of fresh produce throughout the supply chain. The company provides an ethylene-detection device that determines ripeness by calculating the ethylene gas produced by fruit and maximizes freshness and reduces spoilage of fruit. Strella Biotechnology, Inc. was founded in 2018 and is based in Philadelphia, Pennsylvania.
dbt Labs, founded in 2016 and based in Philadelphia, operates a software-as-a-service platform that specializes in open-source data engineering. The company's primary offering, the data build tool (dbt), empowers data analysts and engineers to organize, cleanse, and transform data for analysis using SQL. This platform facilitates data modeling, event tracking, and KPI measurement, enabling users to build efficient data transformation workflows. In addition to its core software, dbt Labs provides training and consulting services in data analytics, supporting organizations in leveraging their data more effectively. Through its mission to enhance the creation and dissemination of organizational knowledge, dbt Labs positions itself as a vital resource for businesses seeking to improve their data analytics capabilities.
We believe everyone should have the opportunity to live their best lives and age with dignity. That’s why we’re reinventing primary care with an approach designed to profoundly improve the healthcare and aging experience for older adults and their loved ones.
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.
PeerSpace, Inc. operates a marketplace that connects companies and individuals with short-term workspaces. Founded in 2013 and headquartered in San Francisco, the platform allows users to search, message, and book a diverse range of spaces, including corporate and private event venues, photo studios, conference rooms, and unique locations like converted warehouses and sports car museums. The service caters to a broad clientele across major U.S. cities, including the San Francisco Bay Area, Los Angeles, New York, Seattle, Austin, and Chicago. By streamlining the booking process, PeerSpace enables clients to easily access various locations for purposes such as off-site meetings, film and photography shoots, or social events, while providing hosts the opportunity to monetize their under-utilized properties.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.